174 related articles for article (PubMed ID: 32525730)
21. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
23. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Laetsch TW; Maude SL; Rives S; Hiramatsu H; Bittencourt H; Bader P; Baruchel A; Boyer M; De Moerloose B; Qayed M; Buechner J; Pulsipher MA; Myers GD; Stefanski HE; Martin PL; Nemecek E; Peters C; Yanik G; Khaw SL; Davis KL; Krueger J; Balduzzi A; Boissel N; Tiwari R; O'Donovan D; Grupp SA
J Clin Oncol; 2023 Mar; 41(9):1664-1669. PubMed ID: 36399695
[No Abstract] [Full Text] [Related]
24. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
25. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective.
Wang XJ; Wang YH; Ong MJC; Gkitzia C; Soh SY; Hwang WYK
Clinicoecon Outcomes Res; 2022; 14():333-355. PubMed ID: 35535300
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.
Fowler NH; Dickinson M; Ghosh M; Chen AI; Andreadis C; Tiwari R; Masood A; Ramos R; Jousseaume E; Thieblemont C; Dreyling M; Schuster SJ
Transplant Cell Ther; 2023 Jan; 29(1):60.e1-60.e4. PubMed ID: 36182104
[TBL] [Abstract][Full Text] [Related]
29. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Si Lim SJ; Grupp SA; DiNofia AM
Pediatr Blood Cancer; 2021 Sep; 68(9):e29123. PubMed ID: 34061452
[TBL] [Abstract][Full Text] [Related]
30. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
31. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
[TBL] [Abstract][Full Text] [Related]
32. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Cope S; Ayers D; Zhang J; Batt K; Jansen JP
BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
[TBL] [Abstract][Full Text] [Related]
33. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
Front Immunol; 2023; 14():1280580. PubMed ID: 38292483
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland.
Moradi-Lakeh M; Yaghoubi M; Seitz P; Javanbakht M; Brock E
Adv Ther; 2021 Jun; 38(6):3427-3443. PubMed ID: 34021886
[TBL] [Abstract][Full Text] [Related]
35. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
Andrade AM; Teixeira VR; Pogue R; Figueiredo ACMG; Carvalho JL
Cytotherapy; 2023 Sep; 25(9):930-938. PubMed ID: 37341664
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
[TBL] [Abstract][Full Text] [Related]
38. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
Guo A; Niyazov A; Macaulay D; Terasawa E; Schmerold L; Wu EQ; Krieger S
J Manag Care Spec Pharm; 2017 Jul; 23(7):771-780. PubMed ID: 28650249
[TBL] [Abstract][Full Text] [Related]
39. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
40. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia.
Ma Q; Zhang J; O'Brien E; Martin AL; Agostinho AC
J Comp Eff Res; 2020 Aug; 9(12):849-860. PubMed ID: 32602756
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
